Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Meet Daniel Sheres

Thursday, January 25, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article introduces Daniel Sheres, the Product Manager at Volition Veterinary. It highlights his background and motivations for joining the company. Additionally, it mentions recent advancements such as the automated Nu.Q® Vet Cancer Test and the submission of a manuscript that could lead to a financial milestone.
Price reaction · baseline $22 (2024-01-24 close) · hit pre-market · 6 other VNRX headline(s) in the window, move may be shared
day 0 close
-5.5%
day 1
-2.7%
day 3 · peak
-8.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Daniel Sheres brings valuable experience to Volition Veterinary.
  • The automated Nu.Q® Vet Cancer Test represents a significant innovation.
  • The upcoming manuscript publication may unlock a substantial milestone payment.

Full Press Release Details

Meet Volition Veterinary Product Manager, Daniel Sheres. Learn about his role, his background, what drew him to Volition Veterinary, and more.

Related Articles

• Press Releases Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
• Press Releases Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

Who is Daniel Sheres?

Daniel Sheres is the Product Manager at Volition Veterinary.

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is an automated cancer testing solution for pets.

What milestone is associated with the manuscript submission?

The manuscript publication could unlock a $5 million contractual milestone payment.

What company is Daniel Sheres associated with?

Daniel Sheres is associated with Volition Veterinary.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Volition Veterinary Nu.Q® Vet Cancer Test Daniel Sheres Fujifilm Vet Systems veterinary cancer testing
Last updated: Jan 25, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk